Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Autolus Therapeutics (AUTL) over the last 8 years, with Q3 2025 value amounting to $4.4 million.

  • Autolus Therapeutics' Capital Expenditures fell 5403.07% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.0 million, marking a year-over-year increase of 14951.77%. This contributed to the annual value of $22.1 million for FY2024, which is 10093.76% up from last year.
  • Autolus Therapeutics' Capital Expenditures amounted to $4.4 million in Q3 2025, which was down 5403.07% from $7.3 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Capital Expenditures peaked at $16.1 million during Q4 2021, and registered a low of -$3.9 million during Q3 2021.
  • Over the past 5 years, Autolus Therapeutics' median Capital Expenditures value was $1.5 million (recorded in 2023), while the average stood at $3.8 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 9607.54% in 2022, then skyrocketed by 138522.52% in 2025.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Capital Expenditures stood at $16.1 million in 2021, then tumbled by 96.08% to $633000.0 in 2022, then surged by 133.33% to $1.5 million in 2023, then skyrocketed by 652.34% to $11.1 million in 2024, then tumbled by 60.33% to $4.4 million in 2025.
  • Its Capital Expenditures was $4.4 million in Q3 2025, compared to $7.3 million in Q2 2025 and $8.2 million in Q1 2025.